In head and neck squamous cell cancer (HNSCC), an epidermal growth factor receptor (EGFR) chimeric monoclonal antibody (mAb) (Cetuximab—CTX), is the standard of care of patients intractable with cisplatin, or in case of high recurrence and metastasis [20, 21]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.